PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33411110-9	2022	In addition, rivaroxaban hydroxylation was inhibited by 41.1% in the presence of the CYP2J2-specific inhibitor danazol, which was comparable to the inhibition rate of 43.3% by the CYP3A-specific inhibitor ketoconazole in mixed HLMs.	Ketoconazole	205-217	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	85-91	
24021950-10	2013	CYP2J2 activity in the cell line was inhibited by danazol, astemizole, and ketoconazole in submicromolar range, but also by xenobiotics known to cause cardiac adverse effects.	Ketoconazole	75-87	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	0-6	
23305158-7	2013	A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95% CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95% CI 134%, 174%]).	Ketoconazole	151-163	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	132-138	
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Ketoconazole	96-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	160-166	
33335233-7	2020	Molecular docking of a series of compounds including amiodarone, astemizole, danazol, ebastine, ketoconazole, terfenadine, terfenadone, and arachidonic acid to CYP2J2 confirmed the role of those residues in determining substrate binding and specificity of CYP2J2.	Ketoconazole	96-108	cytochrome P450 family 2 subfamily J member 2	Homo sapiens	256-262